CPSE:BAVABiotechs
Assessing Bavarian Nordic (CPSE:BAVA) Valuation After Positive Paediatric Mpox And Smallpox Trial Update
Regulatory update: EMA review for paediatric mpox and smallpox use
Bavarian Nordic (CPSE:BAVA) has filed Phase 2 data with the European Medicines Agency to extend its MVA-BN mpox and smallpox vaccine indication to children aged 2 to 11. This filing highlights a potential shift in the product’s approved patient group.
See our latest analysis for Bavarian Nordic.
The latest EMA filing comes as Bavarian Nordic’s DKK195.7 share price sits on a 4.3% 1 month share price return and a 36.7% 1 year...